Dyslipidemia in Type 2 Diabetes (0767-034)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00547274

Enrollment

111

Registered

2007-10-22

Start date

2003-07-31

Completion date

2003-11-30

Last updated

2015-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type II, Dyslipidemia

Brief summary

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Interventions

DRUGMK0767

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men and non-pregnant females * Age greater than or equal to 21 years * Stop current diabetes therapy (if applicable) * Stop current statin therapy (if applicable)

Exclusion criteria

* History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin * Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks * Patients requiring treatment with corticosteroids for more than 14 consecutive days * Patients taking warfarin or warfarin-like anti-coagulants * Patients undergoing surgery within 30 days of Visit 1 * Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease * Patients with history of pancreatitis or uncontrolled high blood pressure

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026